Simon Aronson Stack Pdf Files

Simon Aronson to the rescue! In his book The Aronson Approach, he presents a simple variation of the CHSD order, that doesn't have any obvious repetition of colors, while being just as easy to use. Still using CHSD, if the card in your stack is an ace, two, three, or four, just skip to the next suit of the SAME. So far the most popular and used system is Simon Aronson's. Read his book. Before you memorize your own deck, I would study Simon Aronson's and Tamariz's ideas with their stacks. You can also go on Simon Aronson's website, and download 'Memories Are Made of This' (a free.pdf file) Cheers!

I was thinking the other day about tricks that don't involve any physical gimmicks and I thought of a crazy idea that sounds feasible, but would take a lot of time working on. The result is this question: I figure this has already been done in some capacity, but is there a trick out there that involves A LOT of memorization; specifically, memorizing the exact placement of all 52 cards in a deck? I'm working on a packet trick right now that involves memorizing the placement of 7 cards and I'm doing okay at that, I figure once I get that down that I'll want to take it a notch higher.

I'm trying to look for magic that involves memory practice as I think it would be a great and useful mental exercise (I have TBI). Any help would be greatly appreciated! Not sure if I've what you are searching for, but I think this may interest you. One year ago I was searching for a different way to force a card, so I started thinking on it. What elements should have a good force to look natural? With the classic force in mind, the last one was the answer.

But the action may fail, specially if repeated. How to overcome this problem? Starting your routine using a deck with a pre-maded sequence that you can remember. Next step, how to find the exact position of a selection in a 52 deck sequence? You have two ways, using memory or math. Both are mathematically described by a function like F(position) = card The first obviously require only a good memory training. You can made the work easier if you use a repeated (or mirror) sequence every 4,13 or 26 cards.

But if you have to show the entire deck, someone may easily notice the repetition. With maths, you should only have to train on fast and (possibly) easy operations. However, you have to develop a working formula.

While building one, search missing/duplicate results with different position. Without programming knowledge, it may result difficult to find working and not obviouse sequences.

For example, it may be easy to think of an alternate sequence of seed where the next card has a +3 value from the previous, however a ribbon spread will break the magic. Luckily, programming is my job. I had nice a result building one specific sequence, that I used for some month. Right now I don't remember the exact formula, because I stoped using it, but it used a multiplication for 5, and than an addiction.

The added numbers (surely 1 and 2, the other where between 10 and 30) is based on a list, with index module(position,4). Than the result, get another module for 52. This number is the card in the position of a sorted deck 1-13, seed by seed. I loved it because it hasn't any kind of recognizable pattern, but I should admit, was somewhat impractical.

Maybe I can resume that project and extend it for other purpose. Like using programming power for building and verifying new sequences or routines. Maybe this isn't what you're looking for, but there are many tricks that can be done with memorised decks. Tamariz's book is a pretty comprehensive source for this. This involves learning the order of the deck, but also the position of each card (and therefore the card at each position also). It's actually not as hard as it seems and you could have it memorised in a day or two.

Having this knowledge opens up so many doors for possibilities. If however you're talking about memorising a deck or packet during a trick, secretly or as part of the effect, that would be considerably more difficult. It is worth exploring, but I would recommend finding a way to 'appear to memorise' the deck if it forms part of the effect. That's always going to be easier and will achieve the same outcome., that work can be avoided by using a complete stack. That way you can show the entire deck freely and easily learn which card/s have been selected by looking at the one above or below the selection (or by other methods, depending on the selection process).

There's a few guys doing this. Jamie D Grant is one - he does it in under a minute. Here's a link to his PDF Explaining his technique: I haven't read it, but I suspect it's the Loci/Memory Palace technique due to the name. I don't know of any specific tricks that involve memorizing the whole deck legitimately.

Most magicians aren't willing to put the time and effort into developing the skills involved with that. However, those techniques have been around a very long time. As in the Romans used them and I don't think they invented them. So they are actually freely available to pretty much anyone willing to put the energy into researching it. One good article I like is here: - which explains the basics of the Loci/Memory Palace method. Harry Lorrayne's Memory Book covers this a bit, as well as the Linked List and Peg systems.

There's also other programs out there for sale that may be of benefit but I believe it's just a matter of learning the basics and developing from there. Mostly it's about learning to file information correctly. Click to expand.I seem to remember Binary Code being about the colours, not the actual suit/value of the cards. I say your best bet for a whole deck is some form of Memorized stack. I personally use the Aronson stack, but any memorized stack of 52 cards would work, I suppose.

As for memorizing the order of a completely shuffled randomized deck.this would require some extreme mental work, and not something I'd really want to put the effort into for the small satisfaction it would give me. Just not worth the effort in my opinion, but I suppose it could be done if you could come up with a crazy enough story in your head for all 52 cards. Again you're talking some extreme mental work here, but I've no doubt it could be done. Click to expand.If you're at all interested in these topics, I'd definitely recommend Scenic52, as well as Mnemonica. I got both at the very end of last year and its been great so far.

If you take it at the pace in the book you'll be able to memorise an entire deck easily within a couple of weeks, faster if you want to practice more than he recommends. The first time you do it should take 4-5 minutes and it might take a few tries before you do it without mistakes. Whats also great about it is that within the system he teaches for memorising a shuffled deck, you learn the mnemonica stack with it, its just how he has designed it, so Juan's book is an excellent companion to it, Juan's book contains SO much more than the stack itself and the memorisaiton process. Also with Jamie's technique you'll be able to name the location of each card and the card at each location as well as the order. Click to expand.That is correct Christopher, in addition to the Loci system it includes the POA system and a combination of the major system/another numbers system that I cant think of the name right now.

By combining these different techniques its designed so that you also automatically learn the mnemonica stack. Derren Brown also has some great published material on similar topics. By the way, the world record for a single shuffled deck is approximately 24 seconds! A great goal to work towards, but I think the system used for that is a little more compact than this. Thanks for the personal info Wyatt - I've been dipping my toe into memory work here and there but I'm certainly no expert (I'm not familiar with the acronym POA, for instance). Nice to hear from someone who's worked with it.

Maybe I'll pick up Scenic 52 to push me a bit further. Here's the thing I've realized - Memory work isn't nearly as hard as many make it out to be. We think it is, because we're not really trained to use our minds any more (At least in the US). We let ourselves rely on notepads, and cell phones, and Google, and Siri. But I could probably teach you the linked list method in one sentence and you'll never have to write another grocery list in your life. It takes minutes to learn at most.

The Peg system is a little more involved, and requires more maintenance, but again the concept only takes moments to learn. Same with the Loci method. After that it's just a bit of work to integrate it into your habits, and you're good to go.

Just do it and I bet it's easier than it seems. Personally, I use the skills I learn for performance in my daily life. While I haven't done a lot of memory work, I do use it on a regular basis.

Some folks are fine with creating the illusion of having a memory - I say just do it for real so no matter what you can perform it (Whether you've got your prepared deck, or if they just say 'Memorize this!' ) - and it helps you in your life as well.

Here's the thing I've realized - Memory work isn't nearly as hard as many make it out to be. We think it is, because we're not really trained to use our minds any more (At least in the US). We let ourselves rely on notepads, and cell phones, and Google, and Siri. But I could probably teach you the linked list method in one sentence and you'll never have to write another grocery list in your life.

It takes minutes to learn at most. The Peg system is a little more involved, and requires more maintenance, but again the concept only takes moments to learn. Same with the Loci method. After that it's just a bit of work to integrate it into your habits, and you're good to go. Just do it and I bet it's easier than it seems. Click to expand.This is so absolutely true. These memory techniques are very easy to understand and implement, certain things like memorising an entire shuffled deck will take a bit of work, but its still comprised of these simple techniques.

These core techniques can be applied to things like: Remembering people's names, phone numbers and addresses, grocery lists, timetables, scores, lists of random words and just about anything else that contains numbers and letters. So everything haha.

Speedy Go S60v5 Cracked. All these things only take a few minutes to learn and implement. If you've been trying a bit of memory stuff, and you havent read Derren Brown's book Tricks of the Mind then it is a fantastic early step.

Make sure to read the book and not just the audio book, the printed version goes into a lot more detail. It covers all these basic things, Mnemonics, Peg system, Loci system, a Major system variation, names and more. All succinctly and elegantly, he is such an enjoyable author to read. This is just one chapter too, other chapters include: Close up magic, Hypnosis, Body language and Pseudo science. It really is an excellent book.

Click to expand.It depends, I got lazy in a couple of places and left out the suit. Some of the values have similar characters. For instance the Queen of Spades is Audrey Hepburn and the Queen of Diamonds is Julia Roberts. Both are glamorous female celebrities. If the picture isn't clear enough in mind it gets confusing.

Another example is with the Sevens. The Seven of Spades is my deceased grandpa but the Seven of Hearts is my grandma, they both loved to work in the garden so I might picture one of them planting a garden in my living room. When I go through the pictures in my head it gets a little confusing. This video isn't all that it seems either. I'm using the loki method for the most part but I have a magicky safety net to fall back on when I get lost. Guys I'm new to magic and I'm reading a book named 'Memories are made of this' by aronson. I could not understand this part.

Pulse Reading Here’s a simple but quite fooling effect. Have a spectator cut off a packet from the top of the tabled deck, look at the card she’s cut to (the one at the face of her packet), and then shuffle her packet. She then ribbon spreads her shuffled packet face up across the table in front of you. You take the spectator’s wrist, to feel her pulse, ask her to merely think of her card, as you move her hand back and forth across the tabled spread.

Slowly, you lower her hand down until it lands on just one card, say the Seven of Diamonds. And, of course, you’re correct. Because as you move your hand over the cards, you silently and secretly count the number of cards comprising the entire spread. Suppose you count a total of 15 cards; that means that the spectator originally cut to the 15th card (which in the Aronson stack is the 7D). The rest is just acting, as though you’re reading her pulse and being “guided” by it. It can be a quite convincing demonstration.

How did he know that the spectator thought of the 7D when in fact he just ask the spectator to cut the packet and shuffle it. Even if you did memorize the stack how would you know what she though off? Memories Are Made of This is an entire booklet devoted to tricks with a memorized deck. That is, you know what the top card is, the 2nd card, the 3rd and 4th cards, etc. All the way down to the 52nd card. If someone asks you what the 14th card from the top is, you know it. Likewise, if someone asks you where the Queen of Hearts is, you can tell them the exact position from the top (as well as the cards on either side of the QH).

In the trick you described, Simon only needs to know how many cards the spectator cut off. Since she cut off 15 cards (and looked at the bottom card) once you count the packet after it's spread face-up on the table you'll know that she must've looked at the Seven of Diamonds. Hope that helps.

If it's still unclear then you're probably reading a book that's a bit too advanced for you. Memories Are Made of This is an entire booklet devoted to tricks with a memorized deck. That is, you know what the top card is, the 2nd card, the 3rd and 4th cards, etc. All the way down to the 52nd card. If someone asks you what the 14th card from the top is, you know it. Likewise, if someone asks you where the Queen of Hearts is, you can tell them the exact position from the top (as well as the cards on either side of the QH). In the trick you described, Simon only needs to know how many cards the spectator cut off.

Since she cut off 15 cards (and looked at the bottom card) once you count the packet after it's spread face-up on the table you'll know that she must've looked at the Seven of Diamonds. Hope that helps. If it's still unclear then you're probably reading a book that's a bit too advanced for you.

Original Article Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma Alexandra Snyder, M.D., Vladimir Makarov, M.D., Taha Merghoub, Ph.D., Jianda Yuan, M.D., Ph.D., Jesse M. Zaretsky, B.S., Alexis Desrichard, Ph.D., Logan A. Walsh, Ph.D., Michael A. Postow, M.D., Phillip Wong, Ph.D., Teresa S. Ho, B.S., Travis J. Hollmann, M.D., Ph.D., Cameron Bruggeman, M.A., Kasthuri Kannan, Ph.D., Yanyun Li, M.D., Ph.D., Ceyhan Elipenahli, B.S., Cailian Liu, M.D., Christopher T.

Harbison, Ph.D., Lisu Wang, M.D., Antoni Ribas, M.D., Ph.D., Jedd D. Wolchok, M.D., Ph.D., and Timothy A. Chan, M.D., Ph.D.

N Engl J Med 2014; 371:2189-2199 DOI: 10.1056/NEJMoa1406498. Results Malignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set consisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P=0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neoantigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti–CTLA-4 antibodies.

Predicted neoantigens activated T cells from the patients treated with ipilimumab. Immune checkpoint blockade has led to durable antitumor effects in patients with metastatic melanoma, non–small-cell lung cancer, and other tumor types, but the factors determining whether a patient will have a response remain elusive. The fully human monoclonal antibodies ipilimumab and tremelimumab block cytotoxic T-lymphocyte antigen 4 (CTLA-4), resulting in T-cell activation. Some studies have established correlations between outcomes with ipilimumab and peripheral-blood lymphocyte count, markers of T-cell activation, an “inflammatory” microenvironment, and maintenance of high-frequency T-cell receptor clonotypes. The relationship among the genomic landscape of the tumor, the mutational load, and the benefit from treatment remains obscure. The immunogenicity resulting from nonsynonymous melanoma mutations has been shown in a mouse model, and the antigenic diversity of human melanoma tumors has been modeled in silico and in melanoma-specific CD8 T-cell responses after treatment with ipilimumab. Effector and helper T-cell function and regulatory T-cell depletion are necessary for the efficacy of CTLA-4 blockade, but there is not an association between a specific HLA type and a clinical benefit.

Melanomas have very high mutational burdens (0.5 to >100 mutations per megabase) as compared with other solid tumors. Elegant studies have shown that somatic mutations can give rise to neoepitopes and that these may serve as neoantigens. We conducted a study to determine whether the genetic landscape of a tumor affects the clinical benefit provided by CTLA-4 blocking agents. Sample Acquisition and DNA Preparation For the discovery set, we conducted whole-exome sequencing of DNA from tumors and matched normal blood from 25 ipilimumab-treated patients.

A validation set included an additional 39 patients, of whom 5 were treated with tremelimumab. Primary tumor samples and matched normal peripheral-blood specimens were obtained after the patients had provided written informed consent. DNA was extracted, and exon capture was performed with the use of the SureSelect Human All Exon 50-Mb kit (Agilent Technologies). Enriched exome libraries were sequenced on the HiSeq 2000 platform (Illumina) to provide a mean exome coverage of more than 100× (Memorial Sloan Kettering Cancer Center Genomics Core and Broad Institute). Mutational Landscape of Melanomas from the Study Patients Baseline patient characteristics are shown in Table 1 Clinical Characteristics of the Patients in the Discovery and Validation Sets, According to Clinical Benefit from Therapy.

(for more detailed information, see Tables S1 and S2 in the ). The study involved patients with and those without a long-term clinical benefit from therapy (CTLA-4 blockade alone or CTLA-4 blockade with resection of an isolated stable or nonresponding lesion). A long-term clinical benefit was defined by radiographic evidence of freedom from disease or evidence of a stable or decreased volume of disease for more than 6 months. Lack of a long-term benefit was defined by tumor growth on every computed tomographic scan after the initiation of treatment (no benefit) or a clinical benefit lasting 6 months or less (minimal benefit). Representative scans are shown in Figure 1 Paired Pretreatment and Post-Treatment Computed Tomographic Scans.

In Panel A, the scans on the top were obtained on January 2, 2011, and August 26, 2013, and the scans on the bottom were obtained on September 6, 2011, and January 14, 2013. In Panel B, the scans were obtained on August 13, 2009, and January 9, 2010. Autodesk Inventor Professional 2013 Crack Free Download. , and Fig. To determine the genetic features associated with a sustained benefit from CTLA-4 blockade, we analyzed DNA in tumor and matched blood samples using whole-exome sequencing. In the discovery set, we generated 6.4 Gb of mapped sequence, with more than 99% of the target sequence covered to at least 10× depth and a mean exome coverage of 103× (Table S3 and Fig. The wide ranges of mutational burdens ( Figure 2 Mutational Landscape of Tumors According to Clinical Benefit from Ipilimumab Treatment. Panel A shows the mutational load (number of nonsynonymous mutations per exome) in the discovery and validation sets, according to status with respect to a clinical benefit from therapy.

Panel B depicts the Kaplan–Meier curves for overall survival in the discovery set for patients with more than 100 nonsynonymous coding mutations per exome and patients with 100 or fewer mutations., and Table S3 in the ) and recurrent and driver mutations (Fig. S2C and S2D and Table S4 in the ) among samples were consistent with previously reported findings. The ratio of transitions to transversions (Fig.

S2E in the ) and the frequency of nucleotide changes (Fig. S2F in the ) were similar in the discovery and validation sets. No gene was universally mutated across patients with a sustained benefit. Association between Mutational Burden and Clinical Benefit We hypothesized that an increased mutational burden in metastatic melanoma samples would correlate with a benefit from CTLA-4 blockade. There was a significant difference in mutational load between patients with a long-term clinical benefit and those with a minimal benefit or no benefit, both in the discovery set (P=0.01 by the Mann–Whitney test) and in the validation set (P=0.009 by the Mann–Whitney test) (, and Table S5 in the ). In the discovery set, a high mutational load was significantly correlated with improved overall survival (P=0.04 by the log-rank test) ( ), and there was a trend toward improved survival in the validation set (Fig.

S3A in the ). The latter set included eight patients with nonresponding tumors who otherwise had systemic disease control, which may confound the relationship between mutational load and survival. Further subdivision into four clinical categories was suggestive of a dose–response relationship in the discovery set (Fig. S3B in the ). These data indicate that a high mutational load correlates with a sustained clinical benefit from CTLA-4 blockade but that a high load alone is not sufficient to impart a clinical benefit, because there were tumors with a high mutational burden that did not respond to therapy. Somatic Neoepitopes in Responding Tumors and Efficacy of CTLA-4 Blockade MHC class I presentation and cytotoxic T-cell recognition are required for ipilimumab activity.

Because mutational load alone did not explain a clinical benefit from CTLA-4 blockade, we hypothesized that the presence of specific tumor neoantigens might explain the varied therapeutic benefit. To identify these neoepitopes, we developed a bioinformatic pipeline incorporating prediction of MHC class I binding, modeling of T-cell receptor binding, patient-specific HLA type, and epitope-homology analysis (see the Methods section and Fig. We created a computational algorithm, called NAseek, to translate all nonsynonymous missense mutations into mutant and nonmutant peptides (see the Methods section and Fig. We examined whether a subgroup of somatic neoepitopes would alter the strength of peptide–MHC binding, using patient-specific HLA types (Table S3 in the ). We first compared the overall antigenicity trend of all mutant versus nonmutant peptides. In aggregate, the mutant peptides were predicted to bind MHC class I molecules with higher affinity than the corresponding nonmutant peptides (Fig. Using only peptides predicted to bind to MHC class I molecules (binding affinity, ≤500 nM), we searched for conserved stretches of amino acids shared by multiple tumors.

Using the methods described in the Methods section in the, we identified shared, consensus sequences. We identified a number of tetrapeptide sequences that were shared by patients with a long-term clinical benefit but completely absent in patients with a minimal benefit or no benefit ( Figure 3 Association of a Neoepitope Signature with a Clinical Benefit from CTLA-4 Blockade.

Candidate neoepitopes were identified by means of mutational analysis, as described in the Methods section in the. Panel A shows a heat map of candidate tetrapeptide neoantigens that were present in patients with a long-term clinical benefit but absent in patients with a minimal benefit or no benefit in the discovery set (comprising 25 patients). Each row represents a neoepitope; each column represents a patient. The vertical red line indicates the tetrapeptide signature associated with a response to blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4).

The exact tetrapeptides, chromosomal loci, and nonmutant and mutant nonamers in which they occur are listed in Table S6 in the. Panel B shows the same information for the validation set (comprising 39 patients). Panel C shows the Kaplan–Meier curves for overall survival in the discovery set for patients with the signature and those without the signature.

Panel D shows the same data for the validation set., and Table S6 in the ). It has been shown that short amino acid substrings comprise conserved regions across antigens recognized by a T-cell receptor. In these experiments, recognition of epitopes was driven by consensus tetrapeptides within the immunogenic peptides, and tetrapeptides within cross-reacting T-cell receptor epitopes were necessary and sufficient to drive T-cell proliferation, findings that are consistent with evidence that this polypeptide length can drive recognition by T-cell receptors. Tetrapeptides are used to model genome phylogeny because they occur relatively infrequently in proteins and typically reflect function. We used the discovery set to generate a peptide signature from the candidate neoepitopes. This analysis initially pooled the aforementioned discovery and validation sets to remove low-frequency tetrapeptides in the combined exomes.

Subsequent analysis is restricted to post-filtering peptides (see the Methods section in the ). We found that the tetrapeptides common to each group (candidate neoepitopes) included 101 shared exclusively among patients in the discovery set who had a long-term clinical benefit; this was also independently observed in the validation set (, and Tables S6 and S7 in the ). This set of neoepitopes defines a signature linked to a benefit from CTLA-4 blockade. Because of the size of our discovery set, we cannot exclude the possibility that additional biologically relevant epitopes exist and conversely that there are biologically relevant epitopes that were predicted bioinformatically but were not expressed or presented in patients with a minimal benefit or no benefit (Tables S7A and S7B in the ). Shared tetrapeptide neoepitopes did not simply result from a high mutational load. For example, in the discovery set, the patient with a minimal benefit or no benefit who had the greatest number of mutations (Patient SD7357, who had 1028 mutations) did not share any of the tetrapeptide signatures. This concept was illustrated again in the validation set, in which even tumors from patients with more than 1000 mutations (Patients NR9521 and NR4631) did not respond (Table S3 in the ).

Simulation testing with five different models showed that the association between the neoepitope signature and a long-term clinical benefit was highly significant and was unlikely to have resulted from chance alone (P. In Vitro Validation of Predicted Immunogenic Peptides Translation of next-generation sequencing into in vitro validation of peptide predictions has proven challenging, even in expert hands, with very low published validation rates. In vitro assays are hampered by the paucity of clinical samples, the sensitivity of preserved cells to the freeze–thaw process, the low frequency of anti-neoantigen T cells in clinical samples, and the very low sensitivity of T cells in vitro in the absence of the complex in vivo immunogenic microenvironment. We attempted to optimize prediction by integrating multiple high-throughput approaches (Fig. On the basis of our prediction algorithm, we generated pools of peptides and performed assays of T-cell activation for patients for whom we had sufficient lymphocytes (see the Methods section in the ). Positives pools were observed for three of five patients (Fig.

S10A, S10B, and S10C in the ). We identified the exact peptides for patients with adequate PBMCs. We found a polyfunctional T-cell response to the peptide T ESPFEQHI in Patient CR9306 (Fig. S10D in the ) but not to its nonmutant counterpart, T KSPFEQHI. This response peaked at 60 weeks after the initiation of treatment ( ).

T-cell responses were absent in healthy donors Fig. S10E in the ). T ESPFEQHI had a predicted MHC class I affinity for B4402 of 472 nM, as compared with 18323 nM for T KSPFEQHI. ESPF is a common tetrapeptide found in the response signature and is a substring (positions 176 through 179) of the hepatitis D virus large delta epitope p27 (P ESPFA and ESPFAR). T ESPFEQHI results from a mutation in FAM3C (c.A577G;p.K193E), a gene highly expressed in melanoma (Table S8 in the ). We also found that peptide GLER EGFTF elicited a polyfunctional T-cell response in Patient CR0095 (, and Fig.

S10F in the ), whereas nonmutant GLER GGFTF did not. This response peaked at 24 weeks after the initiation of treatment ( ). GLER EGFTF arises from a mutation in CSMD1 (c.G10337A;p.G3446E), which is also highly expressed in melanoma (Table S8 in the ), and the peptide has 80% homology to a known Burkholderia pseudomallei antigen (Immune Epitope Database Reference ID: 1027043).

The lack of T-cell activation may not rule out a given neoantigen because in vitro assays are limited in sensitivity, as described above. Discussion Anti–CTLA-4 and anti–programmed cell death 1 antibodies have resulted in long-term disease control in a subgroup of patients with melanoma. Here, we have illustrated the importance of tumor genetics in defining the basis of the clinical benefit from CTLA-4 blockade. Our observations suggest a number of principles relevant to immunotherapy for cancer. Although a high mutational load is associated with a benefit from immune checkpoint abrogation, this factor alone is not sufficient to impart a clinical benefit.

Rather, there are somatic neoepitopes that are shared by patients with a prolonged benefit and are absent in those without a prolonged benefit. Owing to somatic mutations, a subset of proteins present in the tumor becomes recognized by the immune system as nonself, given their novelty in the tumor context. These concepts were formulated in the discovery set and confirmed in the validation set and will require further prospective study before use as a definitive biomarker.

It is well known in the field of infectious diseases that an individual amino acid within a peptide can affect immunogenicity by altering peptide–MHC or peptide–T-cell receptor interactions. In cancers, the altered amino acid residue resulting from a single missense mutation can create a T-cell epitope from a previously self peptide. In the patients described here, altered amino acids resulting from tumor mutations caused the tumors to display somatic neoepitopes that elicited an antitumor response augmented by CTLA-4 blockade. Our study has limitations. Although large for a genomic study (128 exomes), our sample size was limited, patients had received a variety of previous treatments, and tumor samples were obtained at various time points.

Furthermore, although the panel of somatic neoepitopes (, and Table S6 in the ) may constitute the most important ones, the in vivo relative immunologic contribution of each peptide is unclear. However, data showing that functionally important immunogenic epitopes persisted after treatment with expanded tumor-infiltrating lymphocytes suggest that the response to mutations may persist over time. Although the recapitulation of the neoantigen signature in the validation set suggests that this may provide a generally applicable tool for prediction of a benefit from immunotherapy, further studies will be needed to investigate the role of MHC class II molecules and the relative effects and characteristics of neoantigens in different cancers. Our use of whole-exome sequencing to identify a genetic basis associated with a benefit from CTLA-4 blockade provides proof of principle that tumor genomics can inform responses to immunotherapy.

For the field of cancer genetics, these data suggest a need for an expanded definition of the previous categories of driver and passenger mutations. Our data show that exonic missense mutations in general confer increased MHC class I binding (Fig. S5A and S5B in the ) and confirm the hypothesis that some mutations formerly categorized as passengers may in fact represent “immune determinants.”. Supported by grants from the Frederick Adler Fund, the National Institutes of Health, Swim across America, the Ludwig Trust, the Melanoma Research Alliance, the Stand Up to Cancer–Cancer Research Institute Immunotherapy Dream Team, the Hazen Polsky Foundation, the STARR Cancer Consortium, and the Harry J. Lloyd Charitable Trust and by a Ruth L. Kirschstein National Research Service Award (T32CA009512, to Dr.

Bristol-Myers Squibb, the employer of two authors, did not provide funding for this study. Provided by the authors are available with the full text of this article at NEJM.org. Snyder, Makarov, Merghoub, and Yuan and Drs.

Wolchok and Chan contributed equally to this article. This article was published on November 19, 2014, and last updated on November 12, 2015, at NEJM.org. We thank Martin Miller at Memorial Sloan Kettering Cancer Center (MSKCC) for his assistance with the NetMHC server, Agnes Viale and Kety Huberman at the MSKCC Genomics Core, Annamalai Selvakumar and Alice Yeh at the MSKCC HLA typing laboratory for their technical assistance, and John Khoury for assistance in chart review. References • 1 Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723[Erratum, N Engl J Med 2010;363:1290.] • 2 Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma.

N Engl J Med 2013;369:122-133 • 3 Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-1775 • 4 Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 20-1031 • 5 Gajewski TF, Louahed J, Brichard VG.

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010;16:399-403 • 6 Cha E, Klinger M, Hou Y, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 2014;6:238ra70-238ra70 • 7 Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 20-1091 • 8 Srivastava N, Srivastava PK. Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.

PLoS One 2009;4:e6094-e6094 • 9 Kvistborg P, Philips D, Kelderman S, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 2014;6:254ra128-254ra128 • 10 Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

J Exp Med 2009;206:1717-1725 • 11 Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9-9 • 12 Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer.

Nature 2013;500:415-421 • 13 Segal NH.